Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?
TheFly reported on June 2 that RBC Capital analyst Leonid Timashev increased the firm’s price target on ONC to $436 from $425 while maintaining an Outperform rating on the shares.









